{"id":"entecavir-fuzheng-huayu-tablet","safety":{"commonSideEffects":[{"rate":null,"effect":"Lactic acidosis"},{"rate":null,"effect":"Hepatitis flare upon discontinuation"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Gastrointestinal disturbance (from herbal component)"}]},"_chembl":{"chemblId":"CHEMBL713","moleculeType":"Small molecule","molecularWeight":"277.28"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Entecavir is a nucleoside reverse transcriptase inhibitor that blocks HBV polymerase activity, reducing viral load in chronic hepatitis B patients. Fuzheng Huayu Tablet contains traditional Chinese herbs (including Salvia miltiorrhiza, Silybum marianum, and others) purported to enhance hepatic microcirculation, reduce inflammation, and inhibit hepatic stellate cell activation to slow or reverse liver fibrosis. The combination aims to provide both antiviral and hepatoprotective effects.","oneSentence":"Entecavir inhibits hepatitis B virus reverse transcriptase to suppress viral replication, while Fuzheng Huayu Tablet is a traditional Chinese medicine formulation intended to support liver function and reduce fibrosis.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:39:13.694Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic hepatitis B with evidence of viral replication and/or hepatic fibrosis"}]},"trialDetails":[{"nctId":"NCT02945956","phase":"PHASE4","title":"Treatment of Low-grade Cirrhotic Portal Hypertension Due to Hepatitis B Virus With Fuzheng Huayu and Entecavir","status":"UNKNOWN","sponsor":"ShuGuang Hospital","startDate":"2018-04-05","conditions":"Portal Hypertension","enrollment":192},{"nctId":"NCT02945982","phase":"PHASE4","title":"Treatment of Moderate and Severe Cirrhotic Portal Hypertension Due to HBV With Fuzheng Huayu and Entecavir","status":"UNKNOWN","sponsor":"ShuGuang Hospital","startDate":"2018-04-05","conditions":"Portal Hypertension","enrollment":184},{"nctId":"NCT02241590","phase":"PHASE4","title":"Treatment of Liver Cirrhosis Due to Hepatitis B Virus With Fuzheng Huayu and Entecavir","status":"UNKNOWN","sponsor":"ShuGuang Hospital","startDate":"2014-09","conditions":"Liver Cirrhosis Due to Hepatitis B Virus","enrollment":700},{"nctId":"NCT02241616","phase":"PHASE4","title":"Traditional Chinese Medicine Combined With Entecavir to Treat Refractory Liver Fibrosis in Liver Cirrhosis Due to HBV","status":"UNKNOWN","sponsor":"ShuGuang Hospital","startDate":"2014-09","conditions":"Hepatitis B Virus Related Cirrhosis","enrollment":350}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":6,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Entecavir + Fuzheng Huayu Tablet","genericName":"Entecavir + Fuzheng Huayu Tablet","companyName":"ShuGuang Hospital","companyId":"shuguang-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Entecavir inhibits hepatitis B virus reverse transcriptase to suppress viral replication, while Fuzheng Huayu Tablet is a traditional Chinese medicine formulation intended to support liver function and reduce fibrosis. Used for Chronic hepatitis B with evidence of viral replication and/or hepatic fibrosis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}